Ocumetics Reports Life-Changing Six-Month Results from First-in-Human Study of Accommodating Intraocular Lens
Ocumetics Technology Corp. announced that six-month postoperative results from its first-in-human study of the Ocumetics Accommodating Intraocular Lens show continued vision improvements and meaningful quality-of-life enhancements for patients, with plans to advance to Group Two surgeries.
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has reported highly encouraging six-month results from the first group of patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The outcomes exceed expectations, with all patients experiencing continuing vision improvements and a strong safety profile. Patients who entered the study with severely impaired vision, including one legally blind individual, have achieved stable visual acuity and reported life-changing improvements in daily living, such as reading, driving, and living independently.
“After six months, what stands out most is not just the clinical performance of the Ocumetics Lens, but the profound impact on patients’ quality of life,” said Dean Burns, President and CEO of Ocumetics. “Patients who entered this study with severely impaired vision are now reading, driving, and living independently again.” The company is leveraging surgeon feedback and patient experience to refine the lens design, with updated versions currently in manufacturing and testing to support the planned initiation of Group Two surgeries.
These results validate the technology behind the Ocumetics Lens, which is designed to fit within the eye’s natural lens compartment and use the eye’s natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses. The company’s forward momentum continues as it advances its mission to transform vision correction. Ocumetics will host a webinar on April 22, 2026, at 4:00 PM ET to discuss the six-month results and study updates. Registration is available at www.ocumetics.com/webinar.
The significance of these findings lies in their potential to dramatically improve quality of life for individuals with severe vision impairment. By demonstrating real-world impact beyond clinical metrics, Ocumetics is positioning its accommodating intraocular lens as a transformative solution in ophthalmology. The company’s focus on patient-reported outcomes and ongoing product enhancements suggests a commitment to bringing this technology to broader patient populations.
For further information, contact Dave Burwell, Director of Investor Relations, at dave.burwell@ocumetics.com. This news release contains forward-looking statements subject to risks and uncertainties. The original release is available at www.newmediawire.com.